ライフサイエンスコーパス: fertility preservation

1 need for adjuvant chemoradiation and allows fertility preservation.

2 to allow for the widest array of options for fertility preservation.

3 making about future conception attempts and fertility preservation.

4 ell research and potential future utility in fertility preservation.

5 on risk assessment and available methods for fertility preservation.

6 on risk assessment and available methods for fertility preservation.

7 tand the impact of conditioning decisions on fertility preservation.

8 ddress diverse reproductive needs, including fertility preservation.

9 assist individuals with infertility and for fertility preservation.

10 mplementation of effective interventions for fertility preservation across institutions.

11 ilure are addressed, followed by options for fertility preservation after stem cell transplantation.

12 stfeeding support, and insurance coverage of fertility preservation and assisted reproductive technol

13 stfeeding support, and insurance coverage of fertility preservation and assisted reproductive technol

14 d treatment regimens and allows risk-adapted fertility preservation and comprehensive support during

15 clinical diagnostics, male contraception and fertility preservation and illuminate the regulatory omi

16 Notable needs also include fertility preservation and navigation through the multip

17 with cancer, quality-of-life issues, such as fertility preservation and parenthood, have become an es

18 e checkpoint; however, mechanisms underlying fertility preservation and post-diapause recovery are la

19 ional resources, advocacy for fair access to fertility preservation, and expansion of institutional s

20 sociated gonadotoxicity, current methods for fertility preservation, and new scientific advances in t

21 s opportunities in male reproductive health, fertility preservation, and regenerative medicine.

22 eatment, the evolving information related to fertility preservation, and the ethical issues involved,

23 To preserve the full range of options, fertility preservation approaches should be considered a

24 east cancer were prospectively evaluated for fertility preservation before adjuvant chemotherapy.

25 Nevertheless, consideration of fertility preservation before cancer treatment remains i

26 immediate revascularization, ensuring better fertility preservation, but the best cryopreservation me

27 of sterility, and some patients are offered fertility preservation by cryopreservation of the ovaria

28 trozole and gonadotropins for the purpose of fertility preservation by embryo or oocyte cryopreservat

29 Although unmet needs include addressing fertility preservation, cardiovascular health, and survi

30 patients with cancer should be referred for fertility preservation counselling quickly to help with

31 baseline fertility assessment and facilitate fertility preservation discussions.

32 -related infertility risk and procedures for fertility preservation does not always happen.

33 readily accessible pharmacologic approach to fertility preservation during conventional chemotherapy.

34 The field of oncofertility, or fertility preservation for patients facing a cancer diag

35 ations for ongoing communication methods for fertility preservation for patients who were diagnosed w

36 of fertility-related information and use of fertility preservation (FP) in connection with cancer tr

37 ancer (BC) is the most common indication for fertility preservation (FP) in women of reproductive age

38 ch to ovarian stimulation for the purpose of fertility preservation (FP) in women with breast cancer

39 The practice of fertility preservation (FP) in women with breast cancer

40 ts are unique in many aspects of their care; fertility preservation (FP) is one of the most complex t

41 ussing treatment-related fertility risks and fertility preservation (FP) options with patients and in

42 atient recall of discussion and referral for fertility preservation (FP) show that less than half rec

43 Fertility preservation (FP), including oocyte and embryo

44 t of challenges when considering options for fertility preservation (FP).

45 All approaches to fertility preservation have specific challenges in child

46 n mice, offering promising broad avenues for fertility preservation in cancer patients undergoing che

47 developed a clinical practice guideline for fertility preservation in female patients who were diagn

48 developed a clinical practice guideline for fertility preservation in male patients who are diagnose

49 it should not be recommended as standard for fertility preservation in patients with lymphoma.

50 is review focuses on the current options for fertility preservation in young women facing the risk of

51 Options for fertility preservation include cryopreservation of embry

52 clinical discussions regarding the need for fertility preservation interventions in girls and young

53 ence with these techniques in the setting of fertility preservation is in its infancy.

54 Fertility preservation is often possible in people under

55 nadotropins and letrozole for the purpose of fertility preservation is unlikely to cause substantiall

56 icancer therapy is a promising technique for fertility preservation mainly in children and young wome

57 Fertility preservation methods are used infrequently in

58 have culminated in an increased interest in fertility preservation methods in girls and young women

59 e trials examining the success and impact of fertility preservation methods in people with cancer.

60 Other fertility preservation methods should be considered inve

61 ce and are widely available; other available fertility preservation methods should be considered inve

62 acy and can improve oncological outcomes and fertility preservation of women treated surgically for c

63 ians of children) and be prepared to discuss fertility preservation options and/or to refer all poten

64 ve years and be prepared to discuss possible fertility preservation options or refer appropriate and

65 e cell disease-associated infertility risks, fertility preservation options, pregnancy possibilities

66 Appropriate fertility-preservation options should be offered.

67 communication, and developmental factors to fertility preservation outcomes.

68 can support patients with challenges around fertility preservation, parenting with cancer, financial

69 patients at risk and initiate management for fertility preservation prior to beginning therapy.

70 d recently were changed from experimental to fertility preservation procedures for medical indication

71 emination, assisted reproductive technology, fertility preservation procedures, or use of a gestation

72 reezing and vitrification of whole ovary for fertility preservation purposes, in an ewe model.

73 Options for fertility preservation remain limited but are improving

74 pretreatment patient counselling and use of fertility preservation services.

75 g pretreatment patient counseling and use of fertility preservation services.

76 al support, nutritional, rehabilitative, and fertility preservation services; programme value, includ

77 In these cases, fertility preservation should be discussed and initiated

78 seling and/or treatment; 660 (65.7%) thought fertility preservation should be discussed with women du

79 ility concerns affect treatment decisions or fertility preservation strategies at the time of initial

80 were used to assess fertility counseling and fertility preservation strategies in a modern cohort of

81 minority of women currently pursue available fertility preservation strategies in this setting.

82 ental pretreatment as well as post-treatment fertility preservation strategies, including barriers an

83 docrine therapy for < 5 years; 65 (10%) used fertility preservation strategies.

84 To ensure safety of this fertility preservation strategy, methods are needed to i

85 uture biologic child, there are a variety of fertility preservation techniques that should be conside

86 Some fertility preservation techniques, such as semen and emb

87 ncer should be counseled about the available fertility preservation techniques.

88 A number of fertility-preservation techniques have been developed an

89 Pubertal blockade has implications for fertility preservation, transgender surgical care and ps

90 sk of future infertility against the risk of fertility preservation treatment, and recommendations mu

91 , as well as early noninvasive screening and fertility preservation treatments.

92 ure studies aiming at improved chelation for fertility preservation, whereas NTBI and labile plasma i